Loading…
← CockpitCompetitor Analysis › 600223.SS Lushang Freda Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Lushang Freda Pharmaceutical Co., Ltd. Class A600223.SSCompetitor analysis, valuation and peers

China · CNY·Real Estate›Real Estate Development
Momentum strong 67
Mkt cap
$781M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$5.83M
20-day average traded
Fwd P/E
28.4×
forward earnings
ROIC−WACC
n/a
WACC 11.1%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥5.16
1D-1.9%
1W-4.6%
1M-8.0%
3M-9.3%
6M-19.5%
YTD-29.9%
1Y-33.4%
ATR %3.0%
52w lowhigh38.4% off high

What Lushang Freda Pharmaceutical does

Employees: 3,514

Lushang Freda Pharmaceutical at a glance

Size Lushang Freda Pharmaceutical (600223.SS) is a China Real Estate company (Real Estate Development) with a market value of $781M, the 2642nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.16 on 18 Nov 2026.

Performance Over six months the shares fell 19.5%, against -15.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median -1.5%); the operating margin is 3.9% (peer median 6.2%).

Valuation It trades at 28.4× forward earnings against a peer median of 11.4× (4th most expensive of 8).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 85600223.SS 82
Six months, rebased to 100: Lushang Freda Pharmaceutical against the median of its 20 peers (local-currency closes).

Lushang Freda Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.83BCN¥3.63BCN¥3.96BCN¥4.55BCN¥12.9B
Revenue growth—-8%-13%-65%—
Gross profitCN¥2.20BCN¥1.85BCN¥2.02BCN¥2.05BCN¥3.04B
EBITDAn/aCN¥295MCN¥325MCN¥383MCN¥658M
Net incomeCN¥157MCN¥188MCN¥244MCN¥303MCN¥45.5M
Free cash flowCN¥225MCN¥228MCN¥227MCN¥325MCN¥963M
Capital expenditureCN¥99.2MCN¥110MCN¥157MCN¥211MCN¥166M
Total debtCN¥88.9MCN¥149MCN¥300MCN¥2.18BCN¥9.45B

Quarterly statements and history in the cockpit →

Lushang Freda Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%-40%-20%0%000025002314ARH600708FPAR-A60060300176006830173JMPXAEMBDL600325DIOS19189347600223.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Lushang Freda Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×20×40×60×ARHFPAR-A0173JMPXADIOSMRC600223.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lushang Freda Pharmaceutical is the large dot.

Lushang Freda Pharmaceutical competitors and peer comparison

How Lushang Freda Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lushang Freda Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600223.SSPeer medianRank in peer set
1-month return-8.0%-6.0%8th lowest of 21
6-month return-19.5%-15.8%9th lowest of 20
Distance from 52-week high-38.4%-36.2%10th lowest of 21
Revenue growth (TTM)+1.9%-1.5%9th highest of 21
Operating margin3.9%6.2%10th lowest of 21
Forward P/E28.4×11.4×4th most expensive of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lushang Freda Pharmaceutical 600223.SSChina$781M-20%+2%4%28.4×n/an/a
Shenzhen Tellus 000025.SZChina$781M-15%-60%21%n/an/an/a
Shenzhen New Nanshan Holding (Group) 002314.SZChina$784M-16%-55%-36%n/an/an/a
Archicom ARH.WAPoland$771M-1%+70%16%7.6×n/an/a
Bright Real Estate 600708.SSChina$769M-37%-54%-82%n/an/an/a
FastPartner FPAR-A.STSweden$767M-13%-2%66%11.4×n/an/a
Guanghui Logistics 600603.SSChina$767M-20%-24%13%n/an/an/a
Robyg ROB.WAPoland$763Mn/a+63%15%n/an/an/a
New World Development 0017.HKHong Kong$760M-71%+10%-8%n/an/an/a
Metro Land 600683.SSChina$754M-58%+1,029%-10%n/an/an/a
K. Wah International 0173.HKHong Kong$754M-17%-17%0%62.5×n/an/a
Jm AB JM.STSweden$811M+10%-14%1%34.7×n/an/a
PEXA PXA.AXAustralia$813M-42%+3%13%44.1×n/an/a
Wing Tai W05.SISingapore$815M-10%+168%6%n/an/an/a
Embassy Developments EMBDL.NSIndia$745M-26%-60%-48%n/an/an/a
Zhuhai Huafa Properties 600325.SSChina$744M-44%-18%-16%n/an/an/a
Dios Fastigheter DIOS.STSweden$821M-12%+1%66%8.9×n/an/a
United Overseas Australia UOS.AXAustralia$740M-11%+13%37%n/an/an/a
Sunac China 1918.HKHong Kong$827M-67%-29%-27%n/an/an/a
Morguard MRC.TOCanada$830M-7%-1%53%3.8×n/an/a
NIPPON KANZAI 9347.TJapan$733M+10%+7%6%n/an/an/a

Questions

Which companies are Lushang Freda Pharmaceutical's closest peers?
The cockpit's peer set: Shenzhen Tellus (000025.SZ), Shenzhen New Nanshan Holding (Group) (002314.SZ), Archicom (ARH.WA), Bright Real Estate (600708.SS), FastPartner (FPAR-A.ST), Guanghui Logistics (600603.SS), Robyg (ROB.WA), New World Development (0017.HK).
Is Lushang Freda Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 28.4× against a peer median of 11.4×, 4th most expensive of 8 in its peer set.
How has Lushang Freda Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -19.5% against -15.8% for the median peer; over one year -33.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.